Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Denis Drygin
  • Lorenzo Pinna
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1195-9



CK2 is a serine/threonine (Ser/Thr) protein kinase that can operate as a tetrameric holoenzyme consisting of two catalytically active subunits α and/or α′ and a dimer of regulatory β-subunits or as a monomeric catalytic subunit (α or α′). Its original name “casein kinase 2,” which was derived from CK2 being identified as a kinase capable of phosphorylating casein in vitro, proved to be a misnomer since casein was found not to be a physiologic substrate of CK2.


CK2 was the first protein kinase to be identified in 1954 by Eugene Kennedy, who described the enzyme’s ability to catalyze the phosphorylation of protein substrate by ATP. CK2 possesses several distinct features that distinguish it from the majority of other kinases. It is a highly acidophilic Ser/Thr kinase that atypically phosphorylates tyrosine (Tyr) residues in addition to Ser and Thr and can also utilize GTP, besides ATP, as a phosphate donor. CK2...


Casein Kinase Ellagic Acid Cyclic Peptide Bile Duct Cancer Selective Small Molecule Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Cozza G, Pinna LA, Moro S (2013) Kinase CK2 inhibition: an update. Curr Med Chem 20:671–693CrossRefPubMedGoogle Scholar
  2. Drygin D (2013) CK2 as a logical target in cancer therapy: potential for combining CK2 inhibitors with various classes of cancer therapeutic agents. In: Pinna L (ed) The Wiley-IUBMB series on biochemistry and molecular biology: protein kinase CK2. Wiley-Blackwell, Ames, pp 383–439CrossRefGoogle Scholar
  3. Guerra B, Issinger OG (2008) Protein kinase CK2 in human diseases. Curr Med Chem 15:1870–1886CrossRefPubMedGoogle Scholar
  4. Ruzzene M, Pinna LA (2010) Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 1804:499–504CrossRefPubMedGoogle Scholar
  5. Trembley JH, Chen Z, Unger G, Slaton J, Kren BT et al (2010) Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 36:187–195PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Pimera, Inc.San DiegoUSA
  2. 2.Department of Biological ChemistryUniversity of PaduaPaduaItaly